Citation: | SONG Shujia, PEI Lijian, XU Yan, ZHANG Xue, HUANG Yuguang. Research Progress on the Animal Models of Neuromyelitis Optica Spectrum Disorders-related Neuropathic Pain[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 598-602. DOI: 10.12290/xhyxzz.2022-0647 |
[1] |
Wingerchuk DM, Banwell B, Bennett JL, et al. Interna-tional consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85: 177-189. DOI: 10.1212/WNL.0000000000001729
|
[2] |
Lucchinetti CF, Guo Y, Popescu BF, et al. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica[J]. Brain Pathol, 2014, 24: 83-97. DOI: 10.1111/bpa.12099
|
[3] |
Asseyer S, Cooper G, Paul F. Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies[J]. Front Neurol, 2020, 11: 778. DOI: 10.3389/fneur.2020.00778
|
[4] |
Ayzenberg I, Richter D, Henke E, et al. Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients[J]. Neurol Neuroimmunol Neuroinflamm, 2021, 8: e985. DOI: 10.1212/NXI.0000000000000985
|
[5] |
Kanamori Y, Nakashima I, Takai Y, et al. Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study[J]. Neurology, 2011, 77: 652-658. DOI: 10.1212/WNL.0b013e318229e694
|
[6] |
Qian P, Lancia S, Alvarez E, et al. Association of neuromyelitis optica with severe and intractable pain[J]. Arch Neurol, 2012, 69: 1482-1487. DOI: 10.1001/archneurol.2012.768
|
[7] |
Zhao S, Mutch K, Elsone L, et al. Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life[J]. Mult Scler, 2014, 20: 1658-1661. DOI: 10.1177/1352458514522103
|
[8] |
Zhang X, Xu Y, Pei LJ. Review of Neuromyelitis Optica Spectrum Disorder with Pain-Depression Comorbidity[J]. Chin Med Sci J, 2021, 36: 316-322.
|
[9] |
Asseyer S, Cooper G, Paul F. Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies[J]. Front Neurol, 2020, 11: 778. DOI: 10.3389/fneur.2020.00778
|
[10] |
Zhang X, Pei L, Xu Y, et al. Factors correlated with neuropathic pain in patients with neuromyelitis optica spectrum disorder[J]. Mult Scler Relat Disord, 2022, 68: 104213. DOI: 10.1016/j.msard.2022.104213
|
[11] |
Li X, Xu H, Zheng Z, et al. The risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study[J]. BMC Neurology, 2022, 22: 304. DOI: 10.1186/s12883-022-02841-9
|
[12] |
Grace PM, Loram LC, Christianson JP, et al. Behavioral assessment of neuropathic pain, fatigue, and anxiety in experimental autoimmune encephalomyelitis (EAE) and attenuation by interleukin-10 gene therapy[J]. Brain Behav Immun, 2017, 59: 49-54. DOI: 10.1016/j.bbi.2016.05.012
|
[13] |
Khan N, Woodruff TM, Smith MT. Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods[J]. Pharmacol Biochem Behav, 2014, 126: 13-27. DOI: 10.1016/j.pbb.2014.09.003
|
[14] |
Kwilasz AJ, Green Fulgham SM, Duran-Malle JC, et al. Toll-like receptor 2 and 4 antagonism for the treatment of experimental autoimmune encephalomyelitis (EAE)-related pain[J]. Brain Behav Immun, 2021, 93: 80-95. DOI: 10.1016/j.bbi.2020.12.016
|
[15] |
Iwamoto S, Itokazu T, Sasaki A, et al. RGMa Signal in Macrophages Induces Neutrophil-Related Astrocytopathy in NMO[J]. Ann Neurol, 2022, 91: 532-547. DOI: 10.1002/ana.26327
|
[16] |
Kurosawa K, Misu T, Takai Y, et al. Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody[J]. Acta Neuropathol Commun, 2015, 3: 82. DOI: 10.1186/s40478-015-0259-2
|
[17] |
Hillebrand S, Schanda K, Nigritinou M, et al. Circulating AQP4-specific ao-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat[J]. Acta Neuropathol, 2019, 137: 467-485. DOI: 10.1007/s00401-018-1950-8
|
[18] |
Chan KH, Zhang R, Kwan JSC, et al. Aquaporin-4 autoantibodies cause asymptomatic aquaporin-4 loss and activate astrocytes in mouse[J]. J Neuroimmunol, 2012, 245: 32-38. DOI: 10.1016/j.jneuroim.2012.02.001
|
[19] |
Kinoshita M, Nakatsuji Y, Kimura T, et al. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin[J]. Biochem Biophys Res Commun, 2009, 386: 623-627. DOI: 10.1016/j.bbrc.2009.06.085
|
[20] |
Saini H, Rifkin R, Gorelik M, et al. Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis[J]. BMC Neurol, 2013, 13: 104. DOI: 10.1186/1471-2377-13-104
|
[21] |
Luo J, Xie C, Zhang W, et al. Experimental mouse model of NMOSD produced by facilitated brain delivery of NMO-IgG by microbubble-enhanced low-frequency ultrasound in experimental allergic encephalomyelitis mice[J]. Mult Scler Relat Disord, 2020, 46: 102473. DOI: 10.1016/j.msard.2020.102473
|
[22] |
Xiang W, Xie C, Luo J, et al. Low Frequency Ultrasound With Injection of NMO-IgG and Complement Produces Lesions Different From Experimental Autoimmune Encephalomyelitis Mice[J]. Front Immunol, 2021, 12: 727750. DOI: 10.3389/fimmu.2021.727750
|
[23] |
Ishikura T, Kinoshita M, Shimizu M, et al. Anti-AQP4 autoantibodies promote ATP release from astrocytes and induce mechanical pain in rats[J]. J Neuroinflammation, 2021, 18: 181. DOI: 10.1186/s12974-021-02232-w
|
[24] |
Saadoun S, Waters P, Bell BA, et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice[J]. Brain, 2010, 133: 349-361. DOI: 10.1093/brain/awp309
|
[25] |
Lee CL, Wang KC, Chen SJ, et al. Repetitive intrathecal injection of human NMO-IgG with complement exacerbates disease severity with NMO pathology in experimental allergic encephalomyelitis mice[J]. Mult Scler Relat Disord, 2019, 30: 225-230. DOI: 10.1016/j.msard.2019.02.025
|
[26] |
Zhang H, Verkman AS. Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59[J]. J Autoimmun, 2014, 53: 67-77. DOI: 10.1016/j.jaut.2014.02.011
|
[27] |
Asavapanumas N, Ratelade J, Verkman AS. Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG [J]. Acta Neuropathol, 2014, 127: 539-551. DOI: 10.1007/s00401-013-1204-8
|
[28] |
Marignier R, Ruiza, Cavagna S, et al. Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid[J]. J Neuroinflammation, 2016, 13: 111. DOI: 10.1186/s12974-016-0577-8
|
[29] |
Harada K, Fujita Y, Okuno T, et al. Inhibition of RGMa alleviates symptoms in a rat model of neuromyelitis optica[J]. Sci Rep, 2018, 8: 34. DOI: 10.1038/s41598-017-18362-2
|
[30] |
Geis C, Ritter C, Ruschil C, et al. The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model[J]. Exp Neurol, 2015, 265: 8-21. DOI: 10.1016/j.expneurol.2014.12.015
|
[31] |
Zeka B, Hastermann M, Hochmeister S, et al. Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS[J]. Acta Neuropathol, 2015, 130: 783-798. DOI: 10.1007/s00401-015-1501-5
|
[32] |
Matsumoto Y, Kanamori A, Nakamura M, et al. Sera from patients with seropositive neuromyelitis optica spectral disorders caused the degeneration of rodent optic nerve[J]. Exp Eye Res, 2014, 119: 61-69. DOI: 10.1016/j.exer.2013.12.010
|